(Q54291837)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Bill H. Chang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Suzanne McGoldrick

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

16

Elihu Estey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

15

Ann Woolfrey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Katherine Tarlock

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Todd Cooper

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Thomas Gross

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Steven Neudorf

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Kathleen Adlard

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Phoenix A Ho

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tanya Watt

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tina Templeman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

India Sisler

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Amy Garee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Blythe Thomson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Soheil Meshinchi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Jessica A Pollard

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

8 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

published in

Pediatric Blood Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1048-1054

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

Clinical implications of FLT3 mutations in pediatric AML.

29 February 2020

cites work

1 reference

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

21 January 2018

1 reference

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia

21 January 2018

1 reference

Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution

21 January 2018

1 reference

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

21 January 2018

1 reference

Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia

21 January 2018

1 reference

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

21 January 2018

1 reference

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

21 January 2018

1 reference

Cardiotoxicity associated with targeting kinase pathways in cancer

21 January 2018

1 reference

The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.

21 January 2018

1 reference

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

Cancer therapy-induced left ventricular dysfunction: interventions and prognosis

21 January 2018

1 reference

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

21 January 2018

1 reference

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.

21 January 2018

1 reference

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.25437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25662999%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference